Picture supply: Getty Pictures
With markets up considerably, 2025 has seemingly been a fantastic 12 months for many SIPP and Shares and Shares ISA buyers. However what about subsequent 12 months? Listed here are two shares that I believe deserve nearer consideration.
FTSE 100 inventory
After a large multiyear rally, the BAE Methods (LSE:BA.) share worth peaked above 2,000p in early October. But it has since retreated to round 1,700p, as I sort (30 December), representing a 17.5% fall.
This downward stress seems linked to renewed hopes for a Ukraine peace settlement, with President Trump stating that he thinks President Putin is now severe about peace. Time will inform. Any precise ceasefire could be welcome, however might see the inventory fall additional.
This units up a considerably unusual dynamic for shareholders like myself. I clearly need peace in Ukraine, but in addition don’t prefer to see a falling funding worth. The way to sq. this?
Properly, peace doesn’t out of the blue equal a lot decrease defence spending. Even when there’s a negotiated settlement, Europe has basically modified its perspective to defence spending, whereas navy budgets are rising elsewhere too.
By November, BAE had secured orders of greater than £27bn for the 12 months, together with £4bn for 20 Storm plane for Türkiye. And that doesn’t embrace the UK’s take care of Norway to produce at the least 5 Kind 26 anti-submarine frigates. That is “anticipated to result in a considerable order“.
Subsequent 12 months, income is tipped to rise 7% to £32.8bn, with earnings per share rising round 12% to 84p.
This places the FTSE 100 inventory on a forward-looking earnings a number of of 20.4. That’s not notably costly for a diversified defence big with a large order guide (£75.4bn in June).
Waiting for 2026, I don’t count on defences shares to ship comparable returns (BAE nonetheless rose greater than 40% in 2025, even after the pullback). However for long-term buyers, I reckon BAE is price contemplating at present ranges.
GLP-1 inventory
In distinction, 2025 has been painful for shareholders of Novo Nordisk (NYSE:NVO). The pharma inventory has fallen 39%, as I write. This displays fears that the Wegovy maker has fallen badly behind rival Eli Lilly within the GLP-1 weight-loss medicine house.
Because the summer season of 2025, Novo shares have crashed greater than 60%!
The corporate has additionally confronted stress from on-line pharmacies promoting cheaper compounded variations of its injectable Wegovy therapy. This has seen it ship revenue warnings previously 12 months, in addition to change its CEO.
Nonetheless, Novo lately turned the primary agency to have a GLP-1 oral tablet authorised by the FDA. This got here after a late-stage research confirmed it safely helped sufferers lose a median of 16.6% of their physique weight.
Clearly, a each day Wegovy tablet ought to increase the market alternative to thousands and thousands of chubby people who find themselves frightened of needles. And the agency introduced the beginning dose might be obtainable for simply $149 per 30 days in January 2026 through direct-to-consumer telehealth channels.
This might assist it undercut compounded injectable variations of Wegovy, in addition to reaccelerate gross sales subsequent 12 months. It additionally improves its aggressive standing with Eli Lilly, which isn’t anticipated to get FDA approval for a GLP-1 tablet until March, on the earliest.
Competitors remains to be a danger right here. However with the inventory buying and selling at lower than 15 instances subsequent 12 months’s forecast earnings, I believe it’s a possibility price serious about.
